Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georgine Wienand

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Clinical Nuclear Medicine|January 24, 2023
177 Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With 177 Lu-PSMA-I&TRalph A Bundschuh, Christian H Pfob, Georgine Wienand, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 19, 2023
[<sup>99m</sup>Tc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experienceMatthias Konrad, Andreas Rinscheid, Georgine Wienand, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 28, 2023
An Intrapatient Dosimetry Comparison of <sup>177</sup>Lu-rhPSMA-10.1 and <sup>177</sup>Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate CancerAndreas Rinscheid, Alexander Gäble, Georgine Wienand, et al.
EJNMMI Research|April 26, 2024
Biodistribution and radiation dosimetry of [<sup>99m</sup>Tc]Tc-N4-BTG in patients with biochemical recurrence of prostate cancerAndreas Rinscheid, Alexander Gäble, Georgine Wienand, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 9, 2023
Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [<sup>68</sup>Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid CancerThomas Günther, Nadine Holzleitner, Oliver Viering, et al.
Circulation. Cardiovascular Imaging|November 13, 2024
[<sup>99m</sup>Tc]-PentixaTec SPECT/CT for Imaging of Chemokine Receptor 4 Expression After Myocardial InfarctionAlessandro Liebich, Ralph A Bundschuh, Christian H Pfob, et al.
Clinical Nuclear Medicine|August 2, 2024
Biodistribution and Radiation Dosimetry for 68 Ga-DOTA-CCK-66, a Novel CCK 2 R-Targeting Compound for Imaging of Medullary Thyroid CancerOliver Viering, Andreas Rinscheid, Nadine Holzleitner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 25, 2025
Biodistribution and Radiation Dosimetry of [<sup>68</sup>Ga]Ga-RAYZ-8009, a Glypican 3-Targeting Compound for Imaging of Hepatocellular CarcinomaOliver Viering, Julia Brosch-Lenz, Ralph A Bundschuh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 2, 2024
First Safety and Efficacy Data with the Radiohybrid <sup>177</sup>Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate CancerAlexander Dierks, Alexander Gäble, Andreas Rinscheid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2024
C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy Using [<sup>99m</sup>Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept StudyJohanna S Enke, Kathrin Ritzel, Evelyn Asbach, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Nuclear Medicine|January 24, 2023
177 Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With 177 Lu-PSMA-I&TRalph A Bundschuh, Christian H Pfob, Georgine Wienand, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 19, 2023
[<sup>99m</sup>Tc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experienceMatthias Konrad, Andreas Rinscheid, Georgine Wienand, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 28, 2023
An Intrapatient Dosimetry Comparison of <sup>177</sup>Lu-rhPSMA-10.1 and <sup>177</sup>Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate CancerAndreas Rinscheid, Alexander Gäble, Georgine Wienand, et al.
EJNMMI Research|April 26, 2024
Biodistribution and radiation dosimetry of [<sup>99m</sup>Tc]Tc-N4-BTG in patients with biochemical recurrence of prostate cancerAndreas Rinscheid, Alexander Gäble, Georgine Wienand, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 9, 2023
Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [<sup>68</sup>Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid CancerThomas Günther, Nadine Holzleitner, Oliver Viering, et al.
Circulation. Cardiovascular Imaging|November 13, 2024
[<sup>99m</sup>Tc]-PentixaTec SPECT/CT for Imaging of Chemokine Receptor 4 Expression After Myocardial InfarctionAlessandro Liebich, Ralph A Bundschuh, Christian H Pfob, et al.
Clinical Nuclear Medicine|August 2, 2024
Biodistribution and Radiation Dosimetry for 68 Ga-DOTA-CCK-66, a Novel CCK 2 R-Targeting Compound for Imaging of Medullary Thyroid CancerOliver Viering, Andreas Rinscheid, Nadine Holzleitner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 25, 2025
Biodistribution and Radiation Dosimetry of [<sup>68</sup>Ga]Ga-RAYZ-8009, a Glypican 3-Targeting Compound for Imaging of Hepatocellular CarcinomaOliver Viering, Julia Brosch-Lenz, Ralph A Bundschuh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 2, 2024
First Safety and Efficacy Data with the Radiohybrid <sup>177</sup>Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate CancerAlexander Dierks, Alexander Gäble, Andreas Rinscheid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2024
C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy Using [<sup>99m</sup>Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept StudyJohanna S Enke, Kathrin Ritzel, Evelyn Asbach, et al.
Pageof 2